Smith & Nephew plc 在全球开发、制造、营销和销售医疗器械。公司总部位于英国沃特福德。
财务指标
营业收入
2026-06-30
$30.97亿
2025-12-31
$32.03亿
2025-06-30
$29.61亿
2024-12-31
$29.83亿
营业支出
2026-06-30
$17.48亿
2025-12-31
$17.51亿
2025-06-30
$16.62亿
2024-12-31
$17.76亿
净利润
2026-06-30
$3.03亿
2025-12-31
$3.32亿
2025-06-30
$2.93亿
2024-12-31
$1.98亿
净利润率
2026-06-30
9.78%
2025-12-31
10.36%
2025-06-30
9.89%
2024-12-31
6.63%
每股收益
2026-06-30
--
2025-12-31
$0.38
2025-06-30
$0.33
2024-12-31
$0.23
息税折旧摊销前利润
2026-06-30
$7.48亿
2025-12-31
$7.46亿
2025-06-30
$7.02亿
2024-12-31
$9.3亿
有效税率
2026-06-30
20.26%
2025-12-31
20.38%
2025-06-30
19.06%
2024-12-31
19.18%
项目
2026-06-30
2025-12-31
2025-06-30
2024-12-31
营业收入
$30.97亿
$32.03亿
$29.61亿
$29.83亿
营业支出
$17.48亿
$17.51亿
$16.62亿
$17.76亿
净利润
$3.03亿
$3.32亿
$2.93亿
$1.98亿
净利润率
9.78%
10.36%
9.89%
6.63%
每股收益
--
$0.38
$0.33
$0.23
息税折旧摊销前利润
$7.48亿
$7.46亿
$7.02亿
$9.3亿
有效税率
20.26%
20.38%
19.06%
19.18%
常见问题
SNN is the NYSE ticker for Smith & Nephew plc, a global medical technology company. The company develops and markets products across orthopaedics, sports medicine, wound management, and advanced wound care. Smith & Nephew operates in more than 100 countries and serves hospitals, surgeons, and patients worldwide. Its ADRs trade on the New York Stock Exchange under SNN, while its ordinary shares are listed in London. The company has a long history dating back to 1856 and remains focused on medical devices and rehabilitation solutions.
The latest SNN stock price is displayed at the top of this stock detail page, typically with real-time or delayed quotes depending on the data provider. You can also check major financial portals or your brokerage platform. Because SNN trades as an ADR, the quote reflects U.S. market hours and currency conversion from the London-listed ordinary shares. For the most current price and intraday changes, refer to the live data shown on this page rather than relying on outdated figures.
SNN's volatility reflects its role as a large-cap medical technology company with global operations. As an ADR, its U.S. price can be influenced by movements in the London-listed ordinary shares, currency fluctuations between the U.S. dollar and British pound, and broader healthcare sector sentiment. Volatility may increase around earnings releases, regulatory decisions, or product announcements. The stock typically exhibits lower volatility than speculative small-cap stocks but can still react to sector-specific news and macroeconomic shifts.
Useful valuation metrics for SNN include the price-to-earnings ratio, forward P/E, price-to-sales, and enterprise value-to-EBITDA, which help compare the company against peers in medical devices. Because SNN reports in U.S. dollars as an ADR, investors should also consider the underlying ordinary share valuation in London. Dividend yield and free cash flow yield are relevant given the company's payout history. Comparing these metrics over time and against industry averages provides context, but current figures should be taken from the latest data on this page.
Quarterly earnings reports can significantly move SNN stock, especially when revenue, margins, or guidance differ from market expectations. Updates on key product lines, restructuring progress, or litigation can also influence sentiment. Because SNN trades as an ADR, earnings released in London may affect both the ordinary shares and the U.S. listing, with currency translation adding another layer. Investors often watch management commentary on growth drivers and cost controls to gauge future performance, but actual results should be verified from official filings.
Smith & Nephew has historically paid dividends to shareholders, with the ADR SNN generally reflecting the ordinary share dividend after currency conversion and any applicable fees. Dividend amounts and payment schedules can vary based on the company's financial performance and board decisions. For the current dividend rate, yield, and payment dates, check the latest dividend information on this page or in the company's official investor relations disclosures, as these details change over time.